Guiding lupus clinical management: Renal manifestations and lupus nephritis

Guiding lupus clinical management: Renal manifestations and lupus nephritis

Tune into this episode of our 'Guiding lupus clinical management' podcast series and hear from Professors Ed Vital, Liz Lightstone and Brad Rovin as they discuss ACR and EULAR guidance on renal manifestations of lupus and lupus nephritis, along with what that means in practice.

Discussing Lupus: S1PR1-mediated modulation as a treatment target, and obinutuzumab results in SLE

Professor Ed Vital and Professor Chris Edwards discuss two recent studies advancing the treatment landscape in SLE. This episode discusses S1PR1-mediated modulation of immune cell trafficking as a potential upstream therapeutic strategy in SLE, and the efficacy and safety of obinutuzumab when added to standard therapy in adults with active SLE. Through expert-led discussion, this podcast offers practical perspectives for clinicians looking to stay at the forefront of lupus care.

Discussing Lupus: New Phase 2 evidence in SLE and lupus nephritis

Professor Victoria Werth and Professor Chi-Chiu Mok discuss two recent studies advancing the treatment landscape in SLE and lupus nephritis. This episode reviews findings from the Phase 2 TULIP-LN trial, highlighting how anifrolumab treatment leads to rapid reductions in urinary biomarkers of intrarenal inflammation in lupus nephritis, and discusses a single-arm Phase 2 trial evaluating daratumumab in SLE. Through expert-led discussion, this podcast offers practical perspectives for clinicians looking to stay at the forefront of lupus care. To explore the full papers and download accompanying slide decks, visit the Lupus Forum. Stay up to date with the latest research and monthly podcast episodes through this free independent resource: https://lupus-forum.com/

Discussing Lupus: New treatment safety and efficacy and impact of mental health outcomes in SLE

Professor Victoria Werth and Doctor Guillermo J. Pons-Estel highlights the new treatment safety and efficacy and impact of mental health outcomes in SLE. This podcast discusses efficacy and safety of SC anifrolumab in SLE, and the associations between discrimination and PROs and the role of mental health in these associations among a multiracial, multiethnic cohort with SLE. If you are interested in the papers discussed, head on over to the Lupus Forum today! Download our latest slide decks and stay up to date with our monthly podcasts, all through this free independent resource: https://lupus-forum.com/

Discussing Lupus: CM313 and predictors of damage in accrual in SLE

Professor Ed Vital discusses two key publications covered on the Lupus Forum in December. his podcast reviews data from a randomised, double-blind, placebo-controlled Phase Ib/IIa trial of the anti-CD38 monoclonal antibody CM313 in adults with systemic lupus erythematosus (SLE), focusing on safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary efficacy. The episode also examines predictors of damage accrual by organ domain in SLE, highlighting factors associated with long-term disease outcomes. If you are interested in the papers discussed, head on over to the Lupus Forum today! Download our latest slide decks and stay up to date with our monthly podcasts, all through this free independent resource: https://lupus-forum.com/